Non-alcoholic fatty liver disease as a trigger of polymorbidity. Is there a way out of the impasse?

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease that not only affects the liver with the development of complications up to cirrhosis, but also associated by an increased risk of developing such diseases/conditions such as diabetes mellitus, cardiovascular pathology, metabolic syndrome, as well as oncological diseases. In this regard, NAFLD represents a medical and social burden associated with high mortality and a decrease in the quality of life of patients. To increase the awareness of physician about this pathology and a systematic approach to pharmacotherapy, in 2022 For the first time in Russia, a National Consensus on the management of adult patients with NAFLD has been released. According to the consensus, the criteria for rational drug therapy are not only the effect on slowing the progression of liver damage up to the regression of steatosis, steatohepatitis and fibrosis, but also a decrease in cardiometabolic risk factors. Currently, only ursodeoxycholic acid (UDCA) meets these requirements. In addition, this drug has a synergistic lipid-lowering effect when combined with statins, which makes it the drug of choice for the treatment of NAFLD at any stage. Considering the high efficiency and large evidence base, UDCA is included in the recommendations on NAFLD and combined pathology by various medical associations: gastroenterological, cardiological, therapeutic.

全文:

受限制的访问

作者简介

Olga Ostroumova

Russian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0002-0795-8225
SPIN 代码: 3910-6585

Dr. Sci. (Med.), Professor, Head of the Department of Therapy and Polymorbid Pathology n.a. Academician M.S. Vovsi, Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases

俄罗斯联邦, Moscow; Moscow

Svetlana Telkova

Russian Medical Academy of Continuous Professional Education

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0003-1439-7371
俄罗斯联邦, Moscow

Anna Dubinina

Russian Medical Academy of Continuous Professional Education

Email: ostroumova.olga@mail.ru
ORCID iD: 0009-0008-6383-0016
俄罗斯联邦, Moscow

Mariya Klepikova

Russian Medical Academy of Continuous Professional Education

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0003-4258-1889
SPIN 代码: 1718-1030
俄罗斯联邦, Moscow

Aleksey Kochetkov

Russian Medical Academy of Continuous Professional Education

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0001-5801-3742
SPIN 代码: 9212-6010
俄罗斯联邦, Moscow

参考

  1. Клинические рекомендации Минздрава РФ «Неалкогольная жировая болезнь печени у взрослых» Год утверждения: 2022. [Clinical recommendations “Non-alcoholic fatty liver disease in adults”. Year of approval: 2022] [Internet] [cited 2024 Jun 01]. (In Russ.)]. Available from: https://cr.minzdrav.gov.ru/recomend/748_1
  2. Sanyal A.J. NASH: A global health problem. Hepatol Res. 2011;41:670–74. doi: 10.1111/j.1872-034X.2011.00824.x.
  3. Paschos P., Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9–19.
  4. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38. doi: 10.1161/ATVBAHA.107.147538.
  5. Younossi Z.M., Stepanova M., Younossi Y., et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564–568. doi: 10.1136/gutjnl-2019-318813.
  6. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31–41. [Ivashkin V.T., Drapkina O.M., Mayev I.V., et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):31–41. (In Russ.)].
  7. Eslam M., Newsome P.N., Sarin S.K., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–9. doi: 10.1016/j.jhep.2020.03.039.
  8. Day C.P., James O.F. Steatohepatitis: a tale of two «hits»? Gastroenterology. 1998;114(4):842–45. doi: 10.1016/s0016-5085(98)70599-2.
  9. Levene A.P., Goldin R.D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61(2):141–52. doi: 10.1111/j.1365-2559.2011.04145.x.
  10. Manne V., Handa P., Kowdley K.V. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinics in liver disease. 2018;22(1):23–37. doi: 10.1016/j.cld.2017.08.007.
  11. Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2021;134:8–19. doi: 10.1097/CM9.0000000000001263.
  12. Parthasarathy G., Revelo X., Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. Hepatology Communications. 2020;4(4):478–92. doi: 10.1002/hep4.1479.
  13. Haas J.T., Francque S., Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181–205. doi: 10.1146/annurev-physiol-021115-105331.
  14. Polyzos S.A., Mantzoros C.S. Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism: clinical and experimental. 2015;64(1):5–12. doi: 10.1016/j.metabol.2014.10.017.
  15. Marra F., Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280–95. doi: 10.1016/j.jhep.2017.11.014
  16. Khan R.S., Bril F., Cusi K., et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology (Baltimore, Md.). 2019;70(2):711–24. doi: 10.1002/hep.30429.
  17. Lechner K., McKenzie A.L., Krankel N., et al. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. Metab Syndr Relat Disord. 2020;18(4):176–85. doi: 10.1089/met.2019.0115.
  18. Shulman G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease [published correction appears in N Engl J Med. 2014 Dec 4;371(23):2241]. N Engl J Med. 2014;371(12):1131–41. doi: 10.1056/NEJMra1011035.
  19. Petersen M.C., Shulman G.I. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018;98(4):2133–223. doi: 10.1152/physrev.00063.2017.
  20. Low Wang C.C., Hess C.N., Hiatt W.R., Goldfine A.B. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations. Circulation. 2016;133(24):2459–502. doi: 10.1161/CIRCULATIONAHA.116.022194.
  21. White M.G., Shaw J.A., Taylor R. Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction. Diabetes Care. 2016;39(11):2080–88. doi: 10.2337/dc16-0619.
  22. Kim D., Chung G.E., Kwak M.S., et al. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016;14(1):132–38.e4. doi: 10.1016/j.cgh.2015.07.024.
  23. Green C.J., Parry S.A., Gunn P.J., et al. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. Horm Mol Biol Clin Investig. 2018;41(1):/j/hmbci.2020.41.issue-1/hmbci-2018-0038/hmbci-2018-0038.xml. doi: 10.1515/hmbci-2018-0038.
  24. Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-S64. doi: 10.1016/j.jhep.2014.12.012.
  25. Stahl E.P., Dhindsa D.S., Lee S.K., et al. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(8):948–963. doi: 10.1016/j.jacc.2018.11.050.
  26. Targher G., Byrne C.D., Lonardo A., et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600 doi: 10.1016/j.jhep.2016.05.013.
  27. Sinn D.H., Kang D., Chang Y., et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study. J Gastroenterol Hepatol. 2020;35(5):833–839. doi: 10.1111/jgh.14856.
  28. Labenz C., Huber Y., Michel M., et al. Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany. Dig Dis Sci. 2020;65(7):2112–2119. doi: 10.1007/s10620-019-05986-9.
  29. Paik J.M., Henry L., De Avila L., et al. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019;3(11):1459–1471. doi: 10.1002/hep4.1419.
  30. Lee S.B., Park G.M., Lee J.Y., et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study. J Hepatol. 2018;68:1018–24. doi: 10.1016/j.jhep.2017.12.012.
  31. Meyersohn N.M., Mayrhofer T., Corey K.E., et al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol. 2021;19(7):1480–1488.e14. doi: 10.1016/j.cgh.2020.07.030.
  32. Sinn D.H., Cho S.J., Gu S., et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroe.nterology. 2016;151(3):481-488.e1. doi: 10.1053/j.gastro.2016.06.001
  33. Byrne C.D. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med. 2012;29(9):1098–1107. doi: 10.1111/j.1464-5491.2012.03732.x.
  34. Targher G., Marchesini G., Byrne C.D. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: causal association or epiphenomenon? Diabetes Metab 2016;42:142–56. doi: 10.1016/j.diabet.2016.04.002.
  35. Lonardo A., Ballestri S., Marchesini G., et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015;47(3):181–190. doi: 10.1016/j.dld.2014.09.020.
  36. Mantovani A., Byrne C.D., Bonora E., et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018;41:372–38. doi: 10.2337/dc17-1902.
  37. Yamazaki H., Tsuboya T., Tsuji K., et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care 2015;38:1673–9. doi: 10.2337/dc15-0140.
  38. Allen A.M., Hicks S.B., Mara K.C., et al. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity – a longitudinal cohort study. J Hepatol 2019;71:1229–36. doi: 10.1016/j.jhep.2019.08.018.
  39. Mantovani A., Dauriz M., Byrne C.D., et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. Metabolism. 2018;87:1–12. doi: 10.1016/j.metabol.2018.06.004.
  40. Kim G.A., Lee H.C., Choe J., et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2018;68:140–6. doi: 10.1016/j.jhep.2017.09.012.
  41. Targher G., Chonchol M.B., Byrne C.D. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64(4):638–652. doi: 10.1053/j.ajkd.2014.05.019.
  42. Targher G., Byrne C.D. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13(5):297–310. doi: 10.1038/nrneph.2017.16.
  43. Vilar-Gomez E., Calzadilla-Bertot L., Friedman S.L., et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2017;45:332–44. doi: 10.1111/apt.13860.
  44. Musso G., Gambino R., Tabibian J.H., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. doi: 10.1371/journal.pmed.1001680.
  45. Mantovani A., Zaza G., Byrne C.D., et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018;79:64-76. doi: 10.1016/j.metabol.2017.11.003.
  46. Маевская М.В., Котовская Ю.В., Ивашкин В.Т., и др. Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2). [Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., et al. Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv. 2022;94(2). (In Russ.)] doi: 10.26442/00403660.2022.02.201363.
  47. Panzitt K., Fickert P,. Wagner M. Regulation of autophagy by bile acids and in cholestasis – CholestoPHAGY or CholeSTOPagy. Biochim Biophys Acta Mol Basis Dis. 2021;1867(2):166017. doi: 10.1016/j.bbadis.2020.166017.
  48. Wu P., Zhao J., Guo Y., et al. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem Biophys Res Commun. 2020;529(3):834–838. doi: 10.1016/j.bbrc.2020.05.128.
  49. Achufusi TGO, Safadi AO, Mahabadi N. Ursodeoxycholic Acid. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 12, 2023.
  50. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001 Jul;35(1):134-46. doi: 10.1016/s0168-8278(01)00092-7.
  51. Пирогова И.Ю., Яковлева С.В., Неуймина Т.В. и др. Влияние препарата УрСосан на стеатоз и Фиброз печени, а также показатЕли метаболического синдРома у больных с неалкогольной жировой болезнью печени: сравнительное исследование «СФЕРА». Гастроэнтерология (Прил. к журн. Consilium Medicum). 2018;1:7–14. [Pirogova I.Yu., Yakovleva S.V., Neujmina T.V. et al. Pleiotropic effects of Ursosan in non-alcoholic fatty liver disease and metabolic syndrome. Gastroenterology (Suppl. Consilium Medicum). 2018;1:7–14. (In Russ.)]. doi: 10.26442/2414-3529_2018.1.7-14.
  52. Nadinskaia M., Maevskaya M., Ivashkin V., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959–975. doi: 10.3748/wjg.v27.i10.959.
  53. Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю. и др. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей с помощью урсодеоксихолевой кислоты. Терапевтическмй архив. 2014;12:48–52. [Martsevich S.Yu., Kutishenko N.P., Drozdova L.Yu., et al. Ursodeoxycholic acid-enhanced efficiency and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases: The RACURS study. Therapeutic Archive. 2014;86(12):48–52. (In Russ.)]. doi: 10.17116/t erarkh2014861248-52.
  54. Бойцов С.А., Погосова Н.В., Бубнова М.Г., и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;23(6):7–122. [Boitsov S.A., Pogosova N.V., Bubnova M.G., et al. Cardiovascular prevention 2017. Russian national recommendations. Russian Journal of Cardiology. 2018;23(6):7–122. (In Russ.)]. doi: 10.15829/1560-4071-20186-7-122.
  55. Sánchez-García A., Sahebkar A., Simental-Mendía M., Simental-Mendía L.E. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018;135,144–149. Doi: 0.1016/j.phrs.2018.08.008.
  56. Alberts D.S., Martínez M.E., Hess L.M., et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Nat Cancer Inst. 2005;97(11),846–853. doi: 10.1093/jnci/dji144.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2024